Forxiga will maintain its price for 10 months in KOR
By Jung, Sae-Im | translator Kim, Jung-Ju
23.06.01 16:01:21
가나다라
0
Court accepts the suspension of execution request for Forxiga and Xigduo on the 1st
Drugs will maintain their price until Feb 29th, 2024
Succeeded in preventing KRW 23 billion loss that would have risen during the 10 months of suspension of execution
The prices of AstraZeneca’s SGLT-2 inhibitor ‘Forxiga (dapagliflozin)’ and combination drug ‘Xigduo’ will stay as is until February next year.
On the 1st, the Seoul Administrative Court’s 1st Administrative Division accepted the suspension of execution filed by AstraZeneca against the Ministry of Health and Welfare to cancel the drug price cut disposition for Forxiga and Xigduo.
With the court’s ruling, Forxiga and Xigduo will be able to maintain their price until February 29, 2024. The litigation date for the merits of the lawsuit has not been set yet.
The SGLT-2 inhibitors Forxiga and Xigduo are blockbuster diabetes treatments that contain dapagliflozin wh
Jung, Sae-Im (same@dailypharm.com)
If you want to see the full article, please JOIN US (click)